Vistagen to present at the 2024 neuroscience education institute congress

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (sad), an indication for which fasedienol, its lead intranasal pherine product candidate, is in u.s. registration-directed phase 3 development for the acute treatment of the disorder, and two additional non-systemic.
VTGN Ratings Summary
VTGN Quant Ranking